1. Home
  2. INDP vs FRSX Comparison

INDP vs FRSX Comparison

Compare INDP & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$3.70

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Logo Foresight Autonomous Holdings Ltd.

FRSX

Foresight Autonomous Holdings Ltd.

HOLD

Current Price

$1.49

Market Cap

4.9M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
INDP
FRSX
Founded
2000
N/A
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
5.2M
4.9M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
INDP
FRSX
Price
$3.70
$1.49
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.5M
1.6M
Earning Date
05-11-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$0.31
52 Week High
$13.24
$3.00

Technical Indicators

Market Signals
Indicator
INDP
FRSX
Relative Strength Index (RSI) 61.21 35.61
Support Level $1.86 $0.83
Resistance Level $3.84 $2.27
Average True Range (ATR) 0.90 0.27
MACD 0.19 -0.04
Stochastic Oscillator 56.56 16.76

Price Performance

Historical Comparison
INDP
FRSX

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

About FRSX Foresight Autonomous Holdings Ltd.

Foresight Autonomous Holdings Ltd is a technology company engaged in the development of 3D perception systems and cellular-based applications. The company designs, develops, and commercializes in-line-of-sight vision systems and beyond-line-of-sight accident prevention solutions through its subsidiaries. Its solutions are based on stereo vision, 3D perception, and V2X technologies, aimed at improving safety by enabling accurate obstacle detection and real-time alerts. The company targets multiple industries, including automotive, defense, agriculture, and heavy equipment.

Share on Social Networks: